<DOC>
	<DOCNO>NCT02041117</DOCNO>
	<brief_summary>1 . It multicenter , open-label , sing arm study evaluate effect treatment Rosuvastatin 10-20mg volume morphology atherosclerotic plague reduce LDL-C level less 70mg/dl . 2 . Ischemic stroke patient enrol within 1 month stroke onset . 3 . Patients visit 0m , 1m , 3m , 6m , 9m , 12m , 18m 24m .</brief_summary>
	<brief_title>Resuvastatin Treatment Symptomatic Middle Cerebral Artery Stenosis Based High-resolution Magnetic Resonance Imaging</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Male female patient 18 75 year age . 2 . Ischemic stroke originate middle cerebral artery ( MCA ) AS stenosis , stroke onset within 1 month . 3 . LDLC level 70mg/dl ( 1.8mmol/L ) , less 250mg/dl ( 6.5mmol/L ) ; triglyceride level less 353mg/dl ( 4.0mmol/L ) . 4. total term statin therapy le 2 month past 1year enter study . （5）3070 % intracranial artery stenosis M1 segment MCA comfirmed CTA MRI least 1 atherosclerotic plaque M1 segment MCA detectable . （6）Female patient must agree use effective form birth control throughout 2year study treatment period . （7）The patient willing enrol remain low cholesterol dietary study duration . （8）The patient must able comply schedule visit , treatment plan laboratory test . （9）Written informed consent provide participate study . 1 . Any hemorrhagic stroke hemorrhagic infarction 2 . Presence cardiac source embolism 3 . Ischemic stroke cause non MCA stenosis 4 . The patient LDL cholesterol ≤ 70mg/dl familial hypercholesterolemia . 5 . Previous treatment target lesion stent , angioplasty , mechanical device , plan perform stag angioplasty within 2 year 6 . Any aneurysm proximal distal stenotic intracranial artery 7 . Intracranial tumor ( except meningioma ) intracranial vascular malformation 8 . Thrombolytic therapy within 24 hour enrollmentnt 9 . The patient plan surgical/endovascular intervention intracranial , carotid , coronary and/or peripheral arterial disease course study . 10 . The patient treat evaluate diagnosed tuberculosis . 11 . The patient history malignant neoplasm within previous 5 year ( exception : curable nonmelanoma skin malignancy ) . 12 . The patient know immunodeficient state ( e.g. , human immunodeficiency virus ) treat immunosuppressive drug include cyclosporine . 13 . The patient clinically significant medical condition , opinion Investigator , could impact patient 's ability successfully complete trial . 14 . Life expectancy patient less 2 year . 15 . The patient take medicine follow : Hormonal therapy , Cyclosporine lipid lower agent : fish oil , garlic essential oil etc . 16 . The patient history recent alcohol abuse , drug abuse significant mental illness . 17 . The patient condition would prevent patient give voluntary informed consent . 18 . The patient inability tolerate oral medication administration . 19 . The patient know suspect allergy study medication ( ) class study medication administer . 20 . The patient finish HRMRI reason . 21 . Pregnancy childbearing potential unwilling use contraception duration study 22 . The patient enrol plan enroll another clinical drug device/interventional trial study . 23 . The patient history epilepsy/seizures . 24 . The patient liver function test &gt; 1.5 time upper limit normal , serum creatinine &gt; 2.0 mg/dL , GFR &lt; 30 ml/min abnormal laboratory value deem clinically significant investigator . 25 . The patient history myopathy . 26 . The patient thyroid stimulate hormone &gt; 1.5xULN . 27 . BMI ≥ 30 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>